Selecting patients with ankylosing spondylitis for tnf inhibitor therapy: Comparison of ASDAS and basdai eligibility criteria

Rheumatology (United Kingdom)

Volumn 51, Issue 8, 2012, Pages 1479-1483

  Fagerli, Karen M ^a   Lie, Elisabeth ^a   Van der heijde, Désirée ^a,b   Heiberg, Marte S ^a   Kaufmann, Cecilie ^c   Rødevand, Erik ^d   Mikkelsen, Knut ^e   Kalstad, Synøve ^f   Kvien, Tore K ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Drammen Hospital   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e Hospital for Rheumatic Diseases   (Norway)

^f UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Ankylosing spondylitis; ASDAS; BASDAI; TNF inhibitor

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; BASDAI SCORING SYSTEM; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; JOINT SWELLING; LONGITUDINAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; ANTIRHEUMATIC AGENTS; C-REACTIVE PROTEIN; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT SELECTION; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865172248     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes057     Document Type: Article

References (15)

1. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
2. Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
3. Braun J, Davis J, Dougados M et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
4. van der Heijde D, Sieper J, Maksymowych WP et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
5. Garrett S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
6. Lukas C, Landewe R, Sieper J et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68: 18-24.
7. van der Heijde D, Lie E, Kvien TK et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:1811-8.
8. Machado P, Landewe R, Lie E et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
9. Glintborg B, Ostergaard M, Krogh NS et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010; 69:2002-8.
10. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44: 1876-86.
11. Brandt J, Listing J, Sieper J et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
12. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
13. Vastesaeger N, Van Der Cruyssen B, Mulero J et al. ASDAS high disease activity may be a better criterion than BASDAI elevation for the treatment of ankylosing spondylitis patients with anti-TNF therapy. Ann Rheum Dis 2011;70(Suppl. 3):127.
14. Rudwaleit M, Claudepierre P, Wordsworth P et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36: 801-8.
15. Arends S, Brouwer E, van der Veer E et al. Baseline predictors of response and discontinuation of TNF-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011;13:R94.